JSPR vs. TNYA, DCGO, BDTX, OCGN, AURA, SLDB, SOPH, CRBU, MGTX, and REPL
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Tenaya Therapeutics (TNYA), DocGo (DCGO), Black Diamond Therapeutics (BDTX), Ocugen (OCGN), Aura Biosciences (AURA), Solid Biosciences (SLDB), SOPHiA GENETICS (SOPH), Caribou Biosciences (CRBU), MeiraGTx (MGTX), and Replimune Group (REPL). These companies are all part of the "medical" sector.
Tenaya Therapeutics (NASDAQ:TNYA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Tenaya Therapeutics has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500.
Tenaya Therapeutics' return on equity of -63.21% beat Jasper Therapeutics' return on equity.
In the previous week, Jasper Therapeutics had 10 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 12 mentions for Jasper Therapeutics and 2 mentions for Tenaya Therapeutics. Jasper Therapeutics' average media sentiment score of 1.45 beat Tenaya Therapeutics' score of 0.79 indicating that Tenaya Therapeutics is being referred to more favorably in the media.
Jasper Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Jasper Therapeutics received 2 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. Likewise, 83.33% of users gave Jasper Therapeutics an outperform vote while only 74.19% of users gave Tenaya Therapeutics an outperform vote.
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Tenaya Therapeutics presently has a consensus target price of $15.40, indicating a potential upside of 254.84%. Jasper Therapeutics has a consensus target price of $64.29, indicating a potential upside of 204.82%. Given Jasper Therapeutics' higher possible upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than Jasper Therapeutics.
Summary
Tenaya Therapeutics and Jasper Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
